RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kaleido Biosciences - Stock

Kaleido Biosciences Market capitalization 2024

Kaleido Biosciences Market capitalization

4,186 USD

Ticker

KLDO

ISIN

US4833471000

WKN

A2PELT

In 2024, Kaleido Biosciences's market cap stood at 4,186 USD, a -50% increase from the 8,372 USD market cap in the previous year.

The Kaleido Biosciences Market capitalization history

YEARREVENUE (undefined USD)GROSS MARGIN (%)NET INCOME (undefined USD)
2025e33.08--
2024e31.5--
2023e30.6--
2022e---
20211.1--
20200.98--
2019---
2018---
2017---
2016---

Kaleido Biosciences Aktienanalyse

What does Kaleido Biosciences do?

Kaleido Biosciences Inc is a biopharmaceutical company specializing in the discovery and development of novel therapeutics for a variety of metabolic and immune disorders. The company, based in Lexington, Massachusetts, was founded in 2015 by David Berry, Michael Fischbach, Geoff von Maltzahn, and Noubar Afeyan. The founders brought together their expertise from various fields to develop a new class of drugs based on the manipulation of the microbial ecosystem in the human gut. The company has developed an innovative business model based on the Microbiome Metabolic Therapies (MMT) platform. This platform utilizes naturally occurring, non-pathogenic microorganisms to modulate specific metabolic pathways in the human body. By manipulating the microbiome, scientists at Kaleido Biosciences can influence specific disease states and develop new therapies for metabolic and immune system disorders. One of the areas of focus for the company is the treatment of various metabolic disorders, with a particular emphasis on regulating carbohydrate metabolism. Kaleido Biosciences uses the MMT platform to modify certain bacteria in the gut. The goal is to shift the balance of the gut flora in a way that promotes or suppresses specific metabolic reactions in the body. Another important area of focus is immunotherapy. The aim is to selectively influence the body's immune system to treat various disease states. Kaleido Biosciences is working on strategies to activate bacteria in the gut and trigger specific immune responses. In recent years, the company has developed several promising products and is currently in the clinical trial phase. One product is an MMT candidate for the treatment of celiac disease, an autoimmune disorder related to gluten digestion. Another product is an MMT candidate for the treatment of hyperammonemia in patients with ornithine transcarbamylase deficiency. Kaleido Biosciences also collaborates closely with various companies and partners to further develop its technology platform and identify new products. In 2018, the company entered into a strategic collaboration agreement with Pfizer to identify and develop a range of MMT candidates for the treatment of metabolic and immune disorders. Overall, Kaleido Biosciences Inc has made remarkable progress in a short period of time and developed an innovative technology platform for the development of new therapeutics for complex disease states. The company has quickly established a solid value creation community of investors, partners, and customers. With continued research efforts, partnership endeavors, and a customer-oriented approach, the future looks bright for Kaleido Biosciences. Kaleido Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Kaleido Biosciences's Market Capitalization

Kaleido Biosciences's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Kaleido Biosciences's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Kaleido Biosciences's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Kaleido Biosciences’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Kaleido Biosciences Stock

What is the current Kaleido Biosciences market capitalization?

The current market capitalization of Kaleido Biosciences is 4,186 USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Kaleido Biosciences.

How has the market capitalization of Kaleido Biosciences developed in recent years?

The market capitalization of Kaleido Biosciences has increased/decreased by -50% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Kaleido Biosciences?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Kaleido Biosciences?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Kaleido Biosciences have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Kaleido Biosciences pay?

Over the past 12 months, Kaleido Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kaleido Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Kaleido Biosciences?

The current dividend yield of Kaleido Biosciences is .

When does Kaleido Biosciences pay dividends?

Kaleido Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kaleido Biosciences?

Kaleido Biosciences paid dividends every year for the past 0 years.

What is the dividend of Kaleido Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kaleido Biosciences located?

Kaleido Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kaleido Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kaleido Biosciences from 6/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/26/2024.

When did Kaleido Biosciences pay the last dividend?

The last dividend was paid out on 6/26/2024.

What was the dividend of Kaleido Biosciences in the year 2023?

In the year 2023, Kaleido Biosciences distributed 0 USD as dividends.

In which currency does Kaleido Biosciences pay out the dividend?

The dividends of Kaleido Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kaleido Biosciences

Our stock analysis for Kaleido Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kaleido Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.